CN109563032A - 作为ppar激动剂的吡咯烷衍生物 - Google Patents

作为ppar激动剂的吡咯烷衍生物 Download PDF

Info

Publication number
CN109563032A
CN109563032A CN201780043426.7A CN201780043426A CN109563032A CN 109563032 A CN109563032 A CN 109563032A CN 201780043426 A CN201780043426 A CN 201780043426A CN 109563032 A CN109563032 A CN 109563032A
Authority
CN
China
Prior art keywords
compound
added
solution
ethyl acetate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780043426.7A
Other languages
English (en)
Other versions
CN109563032B (zh
Inventor
袁之渿
龙超峰
江志赶
陈小新
贺海鹰
刘星
张晓�
刘志强
王俨
高雷雷
龚珍
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Raynovent Biotech Co Ltd
Original Assignee
Guangdong Raynovent Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Raynovent Biotech Co Ltd filed Critical Guangdong Raynovent Biotech Co Ltd
Publication of CN109563032A publication Critical patent/CN109563032A/zh
Application granted granted Critical
Publication of CN109563032B publication Critical patent/CN109563032B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

本发明公开了一类作为PPAR激动剂的吡咯烷衍生物，及其在治疗PPAR受体相关通路的一些疾病(比如非酒精性脂肪性肝炎及并发纤维化、胰岛素抵抗、原发性胆汁性胆管炎、血脂异常症、高脂血症、高胆固醇血症、动脉粥样硬化、高甘油三酯血症、心血管疾病、肥胖症等)中的应用。具体公开了式(I)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN201780043426.7A 2016-07-12 2017-07-12 作为ppar激动剂的吡咯烷衍生物 Active CN109563032B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610547500 2016-07-12
CN2016105475006 2016-07-12
CN2017100873069 2017-02-17
CN201710087306 2017-02-17
PCT/CN2017/092583 WO2018010656A1 (zh) 2016-07-12 2017-07-12 作为ppar激动剂的吡咯烷衍生物

Publications (2)

Publication Number Publication Date
CN109563032A true CN109563032A (zh) 2019-04-02
CN109563032B CN109563032B (zh) 2022-05-20

Family

ID=60952288

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780043426.7A Active CN109563032B (zh) 2016-07-12 2017-07-12 作为ppar激动剂的吡咯烷衍生物

Country Status (9)

Country Link
US (1) US10526320B2 (zh)
EP (1) EP3486231B1 (zh)
JP (1) JP6754899B2 (zh)
KR (1) KR102200264B1 (zh)
CN (1) CN109563032B (zh)
AU (1) AU2017297550B2 (zh)
CA (1) CA3030431C (zh)
RU (1) RU2711991C1 (zh)
WO (1) WO2018010656A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111356676A (zh) * 2017-12-21 2020-06-30 广东众生睿创生物科技有限公司 作为ppar激动剂的吡咯烷衍生物的无定形及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110156648A (zh) * 2019-05-30 2019-08-23 河北科技大学 一种Elafibranor中间体的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008534A1 (en) * 1993-09-20 1995-03-30 Glaxo Wellcome Inc. 3-(3,4-dioxyphenyl)-pyrrolidines as type iv phosphodiesterase inhibitors for the treatment of inflammatory diseases
WO2002017912A1 (en) * 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
WO2007053819A2 (en) * 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
CN101115732A (zh) * 2005-01-04 2008-01-30 塞诺菲-安万特股份有限公司 磺酰基吡咯烷类、其制备方法及用作药物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3637974B2 (ja) * 1993-03-25 2005-04-13 エーザイ株式会社 ピロリジン誘導体
CN1625554A (zh) * 2002-02-01 2005-06-08 诺沃挪第克公司 氨基烷基－取代的氮杂环丁烷、吡咯烷、哌啶与氮杂环庚烷的酰胺
EP1702916A1 (en) 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
FR2908766B1 (fr) * 2006-11-20 2009-01-09 Sanofi Aventis Sa Derives de pyrrole,leur preparation et leur utilisation en therapeutique.
WO2016164201A1 (en) * 2015-04-10 2016-10-13 E I Du Pont De Nemours And Company Substituted cyclic amides as herbicides
US11396493B2 (en) * 2017-12-21 2022-07-26 Guangdong Raynovent Biotech Co., Ltd. Amorphous pyrrolidine derivative as PPAR agonist and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008534A1 (en) * 1993-09-20 1995-03-30 Glaxo Wellcome Inc. 3-(3,4-dioxyphenyl)-pyrrolidines as type iv phosphodiesterase inhibitors for the treatment of inflammatory diseases
WO2002017912A1 (en) * 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
CN101115732A (zh) * 2005-01-04 2008-01-30 塞诺菲-安万特股份有限公司 磺酰基吡咯烷类、其制备方法及用作药物的用途
WO2007053819A2 (en) * 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111356676A (zh) * 2017-12-21 2020-06-30 广东众生睿创生物科技有限公司 作为ppar激动剂的吡咯烷衍生物的无定形及其制备方法
CN111356676B (zh) * 2017-12-21 2022-09-27 广东众生睿创生物科技有限公司 作为ppar激动剂的吡咯烷衍生物的无定形及其制备方法

Also Published As

Publication number Publication date
CN109563032B (zh) 2022-05-20
EP3486231A4 (en) 2019-05-22
KR20190020339A (ko) 2019-02-28
US10526320B2 (en) 2020-01-07
AU2017297550A8 (en) 2019-03-14
EP3486231B1 (en) 2020-05-20
EP3486231A1 (en) 2019-05-22
CA3030431A1 (en) 2018-01-18
AU2017297550B2 (en) 2019-07-11
KR102200264B1 (ko) 2021-01-11
RU2711991C1 (ru) 2020-01-23
US20190225597A1 (en) 2019-07-25
JP6754899B2 (ja) 2020-09-16
JP2019527730A (ja) 2019-10-03
AU2017297550A1 (en) 2019-01-31
WO2018010656A1 (zh) 2018-01-18
CA3030431C (en) 2021-05-11

Similar Documents

Publication Publication Date Title
CN109563032A (zh) 作为ppar激动剂的吡咯烷衍生物
CN109071448A (zh) Ask1抑制剂及其制备方法和应用
CN104812748B (zh) 二氢吡唑gpr40调节剂
CN109071538A (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN104918935B (zh) 二氢吡唑gpr40调节剂
CN105517547A (zh) 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途
JP7346388B2 (ja) ベータ－ヒドロキシ複素環アミンおよび高血糖症の治療におけるそれらの使用
CN105121426A (zh) 吡咯烷gpr40调节剂
CN108884107B (zh) 乙型肝炎病毒表面抗原抑制剂
CN108602757B (zh) 地佐辛类似物
CN109790155A (zh) 噻吩化合物及其合成方法和其在医药上的应用
CN114174282A (zh) 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
CN110372723A (zh) 乙型肝炎病毒表面抗原抑制剂
CN108884103A (zh) 作为免疫调节剂的三并环化合物
CN110382463A (zh) Hdac6选择性抑制剂及其制备方法和应用
BRPI0920936A2 (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
CN109563051A (zh) 作为pde4抑制剂的并环类化合物
CN108884045B (zh) Caspase抑制剂及其药物组合物、用途和治疗方法
AU623205B2 (en) N-pyridinyl-9h-carbazol-9-amines, a process their preparation and their use as medicaments
WO2022247770A1 (zh) 一种含氮杂环化合物、其制备方法及应用
CN109071429A (zh) 丙啶磺酰胺类化合物及其使用方法
TWI839738B (zh) 含氮雜環化合物、其製備方法及應用
CN106279041A (zh) 苯基嘧啶衍生物及其制备方法和用途
WO2024041519A1 (zh) 一种吗啉基喹唑啉类化合物、其药物组合物及应用
CN114555076A (zh) 用于治疗非酒精性脂肪性肝炎的药物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 3406a, jinzhonghuan international business building, 3037 Jintian Road, Fu'an community, Futian street, Futian District, Shenzhen City, Guangdong Province

Applicant after: Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.

Address before: Room 1701-1705, Main Building, Rongyi Building, No. 5 Information Road, Songshan Lake High-tech Industrial Development Zone, Dongguan City, Guangdong Province

Applicant before: Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: 510700 Room 501, building D, 288 Shenzhou Road, Huangpu District, Guangzhou City, Guangdong Province

Applicant after: Guangdong Raynovent Biotech Co.,Ltd.

Address before: 3406a, jinzhonghuan international business building, 3037 Jintian Road, Fu'an community, Futian street, Futian District, Shenzhen, Guangdong 518000

Applicant before: Guangdong Raynovent Biotech Co.,Ltd.

GR01 Patent grant
GR01 Patent grant